Delcath Systems (DCTH) Issues Full Year 2025 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Delcath Systems (DCTH) Issues Full Year 2025 Guidance

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025 7:00 AM EDT

2025 Full Year Total Revenue Guidance of $94 to $98 million
Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access.

2025 Full Year Financial Guidance

The Companys financial outlook for fiscal... More